PhRMA said the participants discussed how Congress can help support development of new, innovative medicines for patients in need.
“America’s biopharmaceutical researchers and scientists are on the frontlines of cutting edge science bringing new treatments and cures to patients,” stated PhRMA president and chief executive officer Stephen Ubl. “I’m excited that our companies will be visiting with members of Congress to share why it’s critical to support pro-innovation policies that continue to allow America to be the leader in biopharmaceutical innovation around the globe.”
PhRMA noted that the face-to-face meetings gave members of Congress the chance to directly connect with researchers and scientists developing innovative treatments and to better understand what drives them.
Researchers also highlighted the progress made by the biopharmaceutical industry in recent years, including efforts to harness the immune system to fight cancer; the discovery of medicines that can cure more than 90 percent of patients with hepatitis C; and the discovery of more than 500 medicines for the 25 million Americans with rare diseases.